Lantheus Medical Imaging Inc. launched a new drug for us in magnetic resonance angiography procedures, Ablavar, that contains a controversial element believed to play a role in causing a debilitating kidney condition in patients with severe renal disease.
The Billerica, Mass.-based company said its gadofosveset trisodium imaging agent is the only such drug approved in the U.S. for use in MRA procedures. It’s designed to evaluate aortoiliac occlusive disease in adults with peripheral vascular disease.